OSAKA, JAPAN, January 16, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that Takeda rang the opening bell at the New York Stock Exchange ("NYSE") on January 15, 2019 (US time). Takeda's American Depository Shares have been listed on the NYSE since December 24, 2018 (US time) under the ticker symbol TAK.
On January 8 (Japan time), Takeda completed its acquisition of Shire plc, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.
Takeda now has an attractive geographic footprint and leading position in Japan, the world’s third-largest market, and in the US, the world’s largest market, and is one of the 10 largest pharmaceutical companies in the world in terms of sales. Takeda’s presence in the US is significantly enhanced: after the merger, Takeda expects the US to account for around 49% of its sales revenue of more than 3 trillion yen. The listing on the NYSE in combination with Takeda’s primary listing on the Tokyo Stock Exchange ("TSE") not only reflects this position, it also gives Takeda access to two of the largest capital markets in the world.
Takeda is the only pharmaceutical company that is listed both on the TSE and the NYSE, and continues to be the largest pharmaceutical company listed on the TSE.
Sixteen members of Takeda’s new Takeda Executive Team ("TET") participated in the ringing of the bell. The TET consists of 20 leaders with 11 nationalities who have extensive experience and outstanding track records and will lead Takeda’s global business into the future.
With an expanded geographical network in around 80 countries and regions worldwide, Takeda is committed to bringing Better Health and Brighter Future to people worldwide by delivering its highly-innovative medicines.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit http://www.asiamerlion.cn
+81 (0) 3-3278-2037